Content uploaded by Ali Sahraian
All content in this area was uploaded by Ali Sahraian on Feb 22, 2016
Content may be subject to copyright.
Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online)
Sch. J. App. Med. Sci., 2015; 3(9D):3387-3390 ISSN 2347-954X (Print)
©Scholars Academic and Scientific Publisher
(An International Publisher for Academic and Scientific Resources)
Delusional disorder joined opioid dependence
JamshidAhmadi1, Ali Sahraian2, Sareh Shariati3, Fatemeh Ghanizadeh Kazerooni4, Zahra Mehdipour5,
Maryam Rayatpisheh6, Saeed Samani7
1Professor of Psychiatry
2Associate Professor of Psychiatry
3,4,5Resident of Psychiatry
Substance Abuse Research Center, Department of Psychiatry,
Shiraz University of Medical Sciences; Shiraz; Iran
Abstract: Delusional disorder allied with opioid dependence is a proceeding conundrum. The main objective is to
portray a patient with delusional disorder affiliated with opioid dependence. In results opioid can persuadeor exist with
delusional disorder. In discussion our findings imply that opioid may evoke delusional disorder or be linked to delusional
disorder. In conclusion to our understanding there is not ample information on this issue, and this conclusion might sum
up a prominent concept to the literature.
Keywords: Delusional disorder; Opioid
Opioids such as methadone are synthetic
preparations of opium. Opium has a long history of
medical utilization on the earth [1, 2, 3]. Methadone is a
pure agonist of opioid mu receptor , but
buprenorphine is a partial agonist and has ceiling, hence
its use has less possibility of overdose and also has little
physical dependence. Methadone and buprenorphine
lessen the incidence of HIV and other issues which are
consequences of opiate dependence. Methadone is
absorbed very well after oral use but buprenorphine is
well absorbed after sublingual administration, reaching
60%–70% of the plasma concentration, but poorly
absorbed when administered orally [4, 5, 6, 7, 8, 9, 10].
Nowadays, prevalence of physical and mental
diseases is ascending in the world [11-30]. Among
mental disorders, substance related disorders, especially
opioids and stimulants connected disorders are moving
up universally. At present, opioids and stimulants
associated mental problems are a growing riddle and
have caused more referrals to inpatient and outpatient
We are now going to demonstrate a homicidal
patient with delusional disorder who slayed his wife. To
our understanding, there are not ample published
reports on this matter; hence, this report may disclose a
We portray a homicidal patient with
impression of delusional disorder assorted with opium
dependence. The case was a retired married late forty
year man with primary school education. He lived with
his family in Fars province located in the south of Iran.
The patient began smoking opium once a while since 5
years prior to hospital admission, then step by step
raised the frequency of opium utilization.
Patient bit by bit developed depression after
appearing of a rough compulsive thought of
unfaithfulness of his wife 2 years prior to hospital
admission. He stepwise developed jealousy and
paranoid delusions, suicidal thoughts, irritability, and
insomnia. In this 2-year period he was brought to a
number of psychiatrists and they advised for admission
in psychiatric hospital but he refused to be admitted.
The patient’s condition was becoming worse
since 5 months prior to admission in which he had a
harsh argument with his wife and murdered her with
knife. Then he was incarcerated. In jail he took
methadone for the treatment of opium dependence.
JamshidAhmadi et al., Sch. J. App. Med. Sci., December 2015; 3(9D):3387-3390
Since he had suicidal attempts in the prison, he was
referred to the psychiatric hospital and was admitted.
During psychiatric interview and mental status
examinations he had depressed mood, suicidal thoughts,
severe agitation, restlessness, paranoid thoughts and
insomnia. In precise physical and neurological
examinations there were not, any abnormal findings.
Urine drug tests were positive for methadone
and benzodiazepine. Serology tests for viral markers
(HIV, HCV and HB Ag) were within normal limit.
According to the medical, psychiatric, and substance
use history and also DSM-5 criteria, he was initially
assumed as major depressive disorder associated or
related to opioid dependence.
During admission, he received methadone 15
mg per day for the treatment of opioid withdrawals,
sertraline 150 mg, propanolol 20 mg, sodium valproate
600 mg, doxepin 50, lorazepam1 mg per day for the
treatment of depression and agitation.
Since he did not responded well to the
prescribed medications, consultation was done with
some experts whom their first impression was
delusional disorder, followed by major depressive
disorder as the second impression.
Electro convulsive therapy (ECT) was started
for the treatment of delusion, agitation, suicidal
thoughts and depression. In addition to ECT, patient
received venlafaxine (extended release form) 225 mg
per day and sertraline was discontinued. After taking 11
sessions of ECT, patient’s condition became much
Delusional disorder or major depressive
disorder could be followed by opium consumption or
accompanied with opium utilization.
These findings suggest that opium might bring
forth delusional disorder/major depressive disorder or
joined delusional disorder/major depressive disorder.
To our knowledge and understanding there is
not ample data on this topic, and this conclusion might
sum up a distinguished concept to the literature.
Beforetime fraction of these findings has been
adopted for printing elsewhere.
Conflict of interests: None
1. Sadock B, Sadock V, Ruiz P; (Editors) Kaplan
&Sadock’S Synopsis of Psychiatry:
Lippincott, Williams and Wilkins, Philadelphia
2. Jonnes J; The rise of the modern addict,
American Journal of public Health, 1995; 85:
3. Brian J; Opium and infant-sedation in 19th
century England, Health Visitor, 1994; 76:
4. Jasinski DR, Pevnick JS, Griffith JD; Human
pharmacology and abuse potential of the
analgesic buprenorphine: a potential agent for
treating narcotic addiction. Archives of
General Psychiatry, 1978; 35: 501–516.
5. Ling W, Charuvastra C, Collins JF, Batki S,
Brown LS Jr, Kintaudi P, et al.;
Buprenorphine maintenance treatment of
opiate dependence: a multicenter randomized
clinical trial. Addiction, 1998; 93: 475–486.
6. Ling W, Rawson RA, Compton MA;
Substitution pharmacotherapies for opioid
addiction: from methadone to LAAM and
buprenorphine. Journal of Psychoactive Drugs,
1994; 26: 119–128.
7. Strain EC, Stitzer ML, Liebson IA, Bigelow
GE; Comparison of buprenorphine and
methadone in the treatment of opioid
dependence. American Journal of Psychiatry,
1994; 151: 1025–1030.
8. Johnson RE, Jaffe JH, Fudala PJ; A controlled
trial of buprenorphine treatment for opioid
dependence. Journal of the American Medical
Association, 1992; 267: 2750–2755.
9. Lewis JW; Buprenorphine. Drug and Alcohol
Dependence, 1985; 14: 363–372.
10. Jasinski DR, Fudala PJ, Johnson RE;
Sublingual versus subcutaneous buprenorphine
in opiate abusers. Clinical Pharmacology and
Therapeutics, 1989; 45: 513–519.
11. MacKay Smith M, Ahmadi J, Pridmore S;
Suicide n Shooting Galleries ASEAN Journal
of Psychiatry, 2015; 16(1): 50-56.
12. Pridmore S, Ahmadi J, Reddy A; Suicide in
the absence of mental disorder. Working paper
of public health. 2012; 6: 1-11.
13. Pridmore S, Brüne M, Ahmadi J, Dale J;
Echopraxia in schizophrenia: possible
mechanisms. Aust N Z J Psychiatry. 2008; 42
14. Pridmore S, Robinson J, Ahmadi J; Suicide for
scrutinizers. Australas Psychiatry. 2007; 15
15. Ahmadi J, Kamel M, Ahmed MG, Bayoumi
FA, Moneenum A; Mental Health of Dubai
Medical College Students. Iran J Psychiatry
Behave Sci. 2012; 6(2): 7983.
JamshidAhmadi et al., Sch. J. App. Med. Sci., December 2015; 3(9D):3387-3390
16. Ahmadi J, Samavatt F, Sayyad M,
Ghanizadeh; A various types of exercise and
scores on the Beck Depression Inventory.
Psychol Rep. 2002; 90(31): 8212.
17. Pridmore S, Ahmdi J, Majeed ZA; Suicide in
Old Norse and Finnish folk stories.
Australasian Psychiatry. 2011; 19(4): 322-324.
18. Ahmadi J, Ahmadi N, Soltani F, Bayat F;
Gender differences in depression scores of
Iranian and German medical students. Iran J
Psychiatry Behav Sci 2014; 8(4): 7073.
19. Pridmore S, Ahmadi J; Two cases of ‘Type 3’
suicide. Australasian Psychiatry. 2010; 18(5):
20. Ahmadi J, Toobaee S, Alishahi M; Depression
in nursing students. J Clin Nurs. 2004; 13(1):
21. Ahmadi J, Pridmor S, Fallahzadeh M; Neurotic
scores in medical students. German J
Psychiatry. 2004; 7: 51-5.
22. Ahmadi J; Human and Pain; Journal of
Healthy Society, 1993; 3(13).
23. Ahmadi J; Behavior therapy and Biobehavior
therapy; A comparative view; Journal of Social
Sciences and Humanities of Shiraz University,
Vol.8. No 1 and 2, fall and spring, 1992-3.
24. Ahmadi J; A view on Biobehavior therapy;
Journal of Pulse “Specific for Refreshment of
Medical Community “Vol.2, November 1992.
25. Ahmadi J; The Future of Psychiatry, (A novel
theory and a new approach), Shiraz, Rahgosha
Press, Second edition, Shiraz University of
Medical Sciences, 1992.
26. Ahmadi J; Behavior Therapy, Shiraz, Shiraz
University Press, Third edition, 1991.
27. Ahmadi J; Emotion, Feeling and Non-verbal
Communication, Shiraz, Rahgosha Press,
Shiraz University of Medical Sciences, 1990.
28. Ahmadi J; Obsessive Compulsive Disorder,
Shiraz, Navid Press, Second edition, Shiraz
University of Medical Sciences, 1989.
29. Pridmore S, Ahmdi J; Usage of download of
psychiatry by Muslim countries. Bulletin of
clinical psychopharmacology. 2011; 21(2):
30. Ahmadi J; Human and Bio-behaviorism (A
new theory and approach), Journal of Healthy
Society. Vol.3, No.14, February 1994.
31. Sahraian A, Sharifian M, Omidvar B,
Prevalence of substance abuse among the
medical students in southern Iran
(2010) Shiraz E Medical Journal, 2010; 11 (4):
32. Ahmadi J; The Effect of Buprenorphine and
Bupropion in the Treatment of
Methamphetamine Dependency and Craving.
Br J Med & Med Res 2015; 10 (2): 14.
33. Ahmadi J, Sahraian A, Dastgheib SA, Mowla
A, Ahmadzadeh L; Management of
Methamphetamine Induced Psychosis by 8
sessions of ECT Sch. J. App. Med. Sci., 2015;
34. Khademalhosseini Z, Ahmadi J,
Khademalhosseini M; Prevalence of Smoking,
and its Relationship with Depression, and
Anxiety in a Sample of Iranian High School
Students. Enliven: Pharmacovigil Drug Saf.
35. Ahmadi J, Amiri A, Ghanizadeh A,
Khademalhosseini M, Khademalhosseini Z,
Gholami Z et al.; Prevalence of Addiction to
the Internet, Computer Games, DVD, and
Video and Its Relationship to Anxiety and
Depression in a Sample of Iranian High School
Students. Iran J Psychiatry Behav Sci. 2014; 8
36. Ahmadi J, Soltani F, Tabatabaee F, et al.;
Substance Use Disorders in Patients with Lung
or Heart Diseases. Sch. J. App. Med. Sci.,
2014; 2(1A): 111120.
37. Ahmadi J, Yazdanfar F; Substance use among
Iranian university students. The International
Journal of Drug Policy. 2002; 13(6): 507-508.
38. Ahmadi J, Ahmed MG; Dubai Medical
College Students’ Attitudes towards Substance
Use. J Addict Res Ther (2013) S6: 005.
39. Ahmadi J, Keshtkar M, Pridmore S;
Methamphetamine Induced Synesthesia: A
Case Report. Am J Addict. 2011; 20: 306.
40. Ahmadi J, Alavi M, Alishahi M; Substance
Use Disorders in a Sample of Iranian
Secondary School Students. Social Indicators
Research, 2004; 65(3): 355-360.
41. Ahmadi J, Kampman K, Osline DM, Pettinati
HM, Dackis C, Sparkman T; Predictors of
Treatment Outcome in Outpatient Cocaine and
Alcohol Dependence Treatment. Am J Addict.
42. Ahmadi J, Kamel M, Ahmed MG, Bayoumi
FA, Moneenum AA; Dubai Medical College
students’ scores on the Beck Depression
Inventory. Iranian Red Crescent Journal
(IRCMJ). 2008; 10(3):169172.
43. Ahmadi J, Benrazavi L, Babaeebeigi M,
Ghanizadeh A, Ghanizadeh M, Pridmore S;
Substance use in a sample of medical patients.
J Psychoactive Drugs. 2008;40 (3):3159.
44. Ahmadi J, Kampman K, Dackis C, Sparkman
T, Pettinati H; Cocaine withdrawal symptoms
identify Type B cocaine dependent patients.
Am J Addict. 2008 ;17 (1): 60-64.
45. Ahmadi J, Kampman K, Dackis C; Outcome
predictors in cocaine dependence treatment
trials. Am J Addict. 2006;15 (6):4349.
JamshidAhmadi et al., Sch. J. App. Med. Sci., December 2015; 3(9D):3387-3390
46. Ahmadi J, Fallahzadeh H, Salami A, Rahman
M, Saleh V, Khaghani M, Babaeebeigi M;
Analysis of opium use by students of medical
sciences. J Clin Nurs. 2006;15 (4):37986.
47. Ahmadi J, Sharifi M, Mohagheghzadeh S,
Dehbozorgi GR, Farrashbandi H,
Moosavinasab M et al.; Pattern of cocaine and
heroin abuse in a sample of Iranian general
population. German J Psychiatry. 2005; 8 (1):
48. Ahmadi J, Majdi B, Mahdavi S, Mohaghegh
M; Mood disorders in opioid dependent
patients. J. Affective Disorders. 2004; 82:
49. Ahmadi J, Maharlooy N, Alishahi M;
Substance abuse: prevalence in a sample of
nursing students. J Clin Nurs. 2004; 13(1):
50. Ahmadi J, Naghshvarian M, Afshari R; Opioid
abuse in male population referred for
mandatory Urine Opioid Screen before
marriage in Shiraz Iran. Iranian J Psychiatry
Behav Sci. 2011; 5(2): 12630.
51. Ahmadi J, Etminan H, Javanmardi H; Reasons
for cessation of opiate use among Iranian
opioids dependants. Addictive Disorders &
Their Treatment. 2003; 2(1):9-12.
52. Ahmadi J, Sharifi M; Cannabis abuse in Iran.
Irish J Med Sci. 2003; 172(1):46.
53. Ahmadi J, Arabi H, Mansouri Y; Prevalence of
substance use among offspring of opioid
addicts. Addict Behav. 2003; 28(3): 5915.
54. Ahmadi J, Rayisi T, Alishahi M; Analysis of
substance use by primary school students.
German J Psychiatry, 2003; 3:56-59.
55. Ahmadi J, Hasani M; Prevalence of substance
use among Iranian high school students.
Addict Behav. 2003; 28(2): 3759.
56. Ahmadi J, Benrazavi L; Substance use among
Iranian physical patients. The International
Journal of Drug Policy. 2002; 13(6): 505-506.
57. Ahmadi J, Benrazavi L; Substance use among
Iranian nephrologic patients. Am J Nephrol.
58. Ahmadi J, Benrazavi L; Substance use among
Iranian surgical patients. The International
Journal of Drug Policy 2002; 13(6): 509-510.
59. Ahmadi J, Benrazavi L; Substance use among
Iranian cardiovascular patients. Eur J Med Res.
2002; 7(2): 8992.
60. Ahmadi J, Fakoor A, Pezeshkian P,
Khoshnood R, Malekpour A; Substance use
among Iranian psychiatric inpatients. Psychol
Rep. 2001; 89(2):3635.
61. Ahmadi J, Khalili H, Jooybar R, Namazi N,
Mohammadagaei P; Prevalence of cigarette
smoking in Iran. Psychol Rep. 2001; 89(2):
62. Ahmadi J, Khalili H, Jooybar R, Namazi N,
Aghaei PM; Cigarette smoking among Iranian
medical students, resident physicians and
attending physicians. Eur J Med Res. 2001;
63. Ahmadi J, Toobaee S, Kharras M, Radmehr
M; Psychiatric disorders in opioid dependants.
Int J Soc Psychiatry. 2003; 49(3): 18591.
64. Ahmadi J, Dehghanian I, Razeghian Jahromi
L; Poly substance induced psychosis Sch. J.
App. Med. Sci., 2015; 3(7D):2693-2695
65. Ahmadi J, Sahraian A, Dastgheib SA, Mani A,
Mowla A, Ahmadzadeh L; ECT and
methamphetamine psychosis: IJMPS, 2015;
66. Ahmadi J, Sahraian A, Dastgheib SA,
Moghimi E, Bazrafshan A; Treatment of
heroin abuse. Sch. Acad. J. Biosci., 2015;
67. Ahmadi J, Ekramzadeh S, Pridmore S;
Remission of Methamphetamine-Induced
Withdrawal Delirium and Craving After
Electroconvulsive Therapy Iran J Psychiatry
Behav Sci. 2015; 9(4):e1793.
68. Ahmadi J, Dehghanian I, Razeghian Jahromi
L; Substance induced disorder. Sch. J. App.
Med. Sci., 2015; 3(7D):2700-2703.
69. Ahmadi J; Excellent Outcome of Psychosis
Induced by Methamphetamine Intoxication
after 20 Sessions of Electro Convulsive
Therapy. J Addict Depend 2015 1(2): 1- 2.
70. Ahmadi J, Pridmore S, Ekramzadeh S;
Successful Use Of Electro Convulsive Therapy
In The Management Of Methamphetamine
Induced Psychosis With Onset During
Intoxication. J Addict & Depend, 2015; 1(1):
71. Ahmadi J; Hashish-Induced Olfactory
Hallucination: A Novel Finding. J Psychiatry,
2015; 18: 330. doi:10.4172/2378-
72. Ahmadi J; Heroin Dependency Treatment: A
New Approach. J Addict Depend 2015; 1(2):
73. Ahmadi J; Tramadol Dependency Treatment:
A New Approach. J Addict Med Ther Sci.,
2015; 2(1): 001-03.